By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Eli Lilly and Company v. Accord Healthcare, Inc.
1:11-cv-00261; filed April 4, 2011 in the District Court of North Carolina
Infringement of U.S. Patent No. 5,919,485 ("Oral 2-Methyl-thieno-benzodiazepine Formulation," issued July 6, 1999) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Lilly's Zyprexa® (olanzapine, used to treat schizophrenia and acute manic episodes associated with bipolar mania). View the complaint here.
Novartis AG v. Kappos
1:11-cv-00659; filed April 1, 2011 in the District Court of the District of Columbia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,807,155 ("IL-17 Antagonistic Antibodies," issued October 5, 2010). View the complaint here.
Elan Corp. PLC et al. v. Mylan Pharmaceuticals Inc.
1:11-cv-00281; filed April 1, 2011 in the District Court of Delaware
• Plaintiffs: Elan Corp. PLC; Elan Pharma International Ltd.
• Defendant: Mylan Pharmaceuticals Inc.
Infringement of U.S. Patent Nos. 6,228,398 ("Multiparticulate Modified Release Composition," issued May 8, 2001) and 6,730,325 (same title, issued May 4, 2004), licensed to Novartis, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Novartis' Focalin® XR (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Takeda Pharmaceutical Co., Ltd. et al. v. Dr. Reddy's Laboratories, Ltd. et al.
1:11-cv-02253; filed April 1, 2011 in the Southern District of New York
• Plaintiffs: Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceuticals LLC; Takeda Pharmaceuticals America, Inc.
• Defendants: Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc.
Infringement of U.S. Patent Nos. 6,664,276 ("Benzimidazole Compound Crystal,", issued December 16, 2003) and 7,790,755 ("Controlled Release Preparation," issued September 7, 2010) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Takeda's Dexilant® (dexlansoprazole, used for the treatment of all grades of erosive esophagitis, maintaining healing of esophagitis, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease). View the complaint here.
Life Technologies Corp. v. Pacific Biosciences of California, Inc.
5:11-cv-01582; filed March 31, 2011 in the Northern District of California
Review of the decision of the Board of Patent Appeals and Interferences awarding priority of invention to PacBio in the interference between U.S. Patent No. 7,329,492 ("Methods for Real-Time Single Molecule Sequence Determination," issued February 12, 2008), assigned to Life Technologies and U.S. Patent Application No. 11/459,182 ("A System and Method for Nucleic Acid Sequencing by Polymerase Synthesis," filed July 21, 2006), assigned to PacBio. View the complaint here.
Lupin Atlantis Holdings S.A. v. Ranbaxy Laboratories Ltd. et al.
2:11-cv-02295; filed March 31, 2011 in the Eastern District of Pennsylvania
• Plaintiff: Lupin Atlantis Holdings S.A.
• Defendants: Ranbaxy Laboratories Ltd.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy, Inc.; Ethypharm S.A.
Infringement of U.S. Patent No. 7,863,331 ("Pharmaceutical Composition Containing Fenofibrate and Method for the Preparation Thereof," issued January 4, 2011) following a Paragraph IV certification as part of Ranbaxy's filing of an ANDA to manufacture a generic version of Lupin's Antara® (fenofibrate, used to treat hypercholesterolemia and hypertriglyceridemia). View the complaint here.
Comments